MRD and Decision-Making in Early-Stage Colorectal Cancer

摘要

Identifying patients with colorectal cancer who are at high risk for recurrence following surgical resection is currently a major challenge. The clinicopathologic characteristics being used to identify at-risk patients have poor predictive value, resulting in under- and overtreatment of a substantial number of patients. The use of circulating tumor DNA (ctDNA) as an early indicator of minimal residual disease (MRD) in early-stage colorectal cancer was the topic of discussion in a recent OncView? featuring insights and perspectives from Christopher Lieu, MD, from the University of Colorado School of Medicine, Denver, and Daniel Ahn, DO, from Mayo Clinic in Phoenix.